Previous 10 | Next 10 |
CAMBRIDGE, Mass., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing orally delivered, systemically acting biologics, today announced that it will host a key opinion leader symposium on the unmet need in mild to moder...
Cancer patients who receive an antibiotic within one month of receiving a checkpoint inhibitor achieve a median survival of just two months. Those who don't take an antibiotic and receive the same treatment achieve a median survival of 26 months, fully 1,200% longer. The significant gap is thoug...
CAMBRIDGE, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing orally delivered, systemically acting biologics, announced today that David Epstein has been appointed chairman of its Board of Directors. Mr. Epste...
CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects, today announced that management will participate in a fireside chat at th...
Evelo Biosciences (EVLO) Q2 2019 Earnings Conference Call August 6, 2019 08:30 ET Company Participants Stefan Riley - Former Executive Officer Simba Gill - Chief Executive Officer Duncan McHale - Chief Medical Officer Mark Bodmer - Chief Scientific Officer Conference Call Pa...
Thinly traded micro cap Evelo Biosciences ( EVLO -10.2% ) is down on average volume in early trade following its release of preliminary data from a Phase 1 study of EDP1815 in patients with mild-to-moderate psoriasis. More news on: Evelo Biosciences, Inc., Healthcare stocks news, Stock...
-EDP1815 was Well Tolerated with No Overall Difference Reported from Placebo- -Patients Dosed with EDP1815 Showed a Reduction in Mean Lesion Severity Score vs. Placebo- -Reductions Observed in Cellular Histological and Blood Immune Cell Biomarkers Consistent with Clinical Respon...
-EDP1815 and EDP1066 were Well Tolerated with No Overall Difference Reported from Placebo- -Clinical Response Observed Consistent with Reductions in Cellular Histological and Blood Immune Cell Biomarkers in Psoriasis Patients at Low Dose of EDP1815- - EDP1815 Phase 2 Initiation Planned...
CAMBRIDGE, Mass., July 30, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects, today announced that it will host a conference ca...
CAMBRIDGE, Mass., July 25, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects, today announced that it has entered into a loan and security agreement fo...
News, Short Squeeze, Breakout and More Instantly...
Evelo Biosciences Inc. Company Name:
EVLO Stock Symbol:
OTCMKTS Market:
Evelo Biosciences Inc. Website:
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...